Avidity Biosciences to Present Preliminary Data From Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living With Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress

Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will join Avidity management to present data from FORTITUDEAvidity to host Vo

PR NewswireMay 30 04:05

Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo

Seeking AlphaMay 25 22:24

Avidity Biosciences(RNA.US) Director Sells US$149.48K in Common Stock

$Avidity Biosciences(RNA.US)$ Director LEVIN ARTHUR A sold 5,000 shares of common stock on May 20, 2024 at an average price of $29.8962 for a total value of $149.48K.Source: Announcement What is state

Futu NewsMay 22 05:50

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Co

PR NewswireMay 22 04:05

Avidity Biosciences Poised for Growth: Buy Rating Affirmed Amidst Encouraging Competitive Landscape

TipRanksMay 21 17:36

PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna

Seeking AlphaMay 20 21:58